Table 1.

Clinical characteristics of patients with sJIA associated with the ability to discontinue canakinumab.

CharacteristicsPatients with sJIA Who FlaredPatients with sJIA Who Remained in Remissionp*
Male, 5 total, n (%)3 (43)2 (40)0.1
Female, 7 total, n (%)4 (57)3 (60)
Previous non-canakinumab biologic use7/8 (87.5)1/8 (12.5)0.03
Disease duration at time of canakinumab discontinuation, yrs, median (IQR)3.4 (2–5.2)1.8 (1.3–3.4)0.04
Age at time of canakinumab discontinuation, yrs, median (IQR)8.9 (7.8–12.7)9.2 (7.5–11.4)0.09
  • * Fisher’s exact test. sJIA: systemic juvenile idiopathic arthritis; IQR: interquartile range.